Insmed reports Q2 EPS ($1.70), consensus ($1.31)

Reports Q2 revenue $107.4M, consensus $104.31M. “Q2 of 2025 heralded another important milestone for patients and Insmed (INSM), with the Phase 2b PAH study of TPIP yielding topline results that surpassed our expectations,” said CEO Will Lewis. “Insmed is now ‘three for three’ in terms of positive clinical trial results for our late-stage assets, and we have a line-up of additional anticipated milestones with the potential to expand our impact on patients expected over the next twelve months. Our teams continue to demonstrate executional excellence as we await the widely anticipated FDA approval and launch of brensocatib in bronchiectasis, advance our TPIP program in both PH-ILD and PAH, prepare for topline data from our Phase 2b BiRCh study of brensocatib in chronic rhinosinusitis without nasal polyps by the end of the year, and progress toward the read-out of our Phase 3 ENCORE study of ARIKAYCE in the first half of 2026. Importantly, each of these events represents an opportunity to fulfill Insmed’s mission to transform the lives of patients with serious diseases.”